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Abstract 
Carnitine palmitoyltransferase 1 (CPT1), catalyzing the transfer of the acyl group from 
acyl-CoA to carnitine to form acylcarnitine, is located at the outer mitochondrial 
membrane.  Because it is easily inactivated by solubilization, expression systems using 
living cells are essential for its functional characterization.  COS7 cells or yeast cells 
are often utilized for this purpose; however, the advantages/disadvantages of the use of 
these cells or the question as to how the CPT1 enzyme expressed by these cells differs 
are still uncertain.  In this study, we characterized the heart/muscle-type isozyme of rat 
CPT1 (CPT1b) expressed by these 2 cellular expression systems.  The mitochondrial 
fraction prepared from yeast cells expressing CPT1b showed 25% higher CPT1 activity 
than that obtained from COS7 cells.  However, the expression level of CPT1b in the 
former was 3.8 times lower than that in the latter; and thus, under the present 
experimental conditions, the specific activity of CPT1b expressed in yeast cells was 
estimated to be approximately 5 times higher than that expressed in COS7 cells.  
Possible reasons for this difference are discussed.   
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Introduction 
   The catabolic reaction of long-chain fatty acids, i.e., β-oxidation, takes place in the 
mitochondrial matrix space.  Because fatty acids cannot permeate into this space, they 
are transported across the mitochondrial inner membrane in the form of acylcarnitines.  
For this, fatty acids are first converted into acyl-CoA by acyl-CoA synthase.  Then, the 
acyl-CoA is converted into acylcarnitine by carnitine palmitoyltransferase 1 (CPT1, EC 
2.3.1.21) located on the outer mitochondrial membrane.  The acylcarnitine thus formed 
is transported across the mitochondrial inner membrane by carnitine/acylcarnitine 
carriers; and carnitine palmitoyltransferase 2 (CPT2), located on the inner mitochondrial 
membrane, carries out the reverse reaction of CPT1 and regenerates acyl-CoAs for the 
process of β-oxidation.  Of these processes, the process of the conversion of acyl-CoA 
into acylcarnitine is known as the rate-limiting step; and CPT1 is regarded as the 
rate-limiting enzyme of β-oxidation (for review, see refs. 1-4).   
   Three isozymes of CPT1, CPT1a, 1b, and 1c, are known to be expressed in 
mammals [5-7].  CPT1a is mainly expressed in the liver and kidney; CPT1b is 
expressed in heart, skeletal muscle, and brown adipose tissue; and CPT1c is mainly 
expressed in the brain and testis.  Functional characterization of these CPT1 isozymes 
is very important to understand how the catabolism of fatty acids is regulated in various 
tissues.  However, the enzymatic characterization of CPT1 is difficult, because this 
enzyme is easily inactivated upon solubilization with detergents [8,9].  For this reason, 
functional analysis of this enzyme is mainly carried out by using expression systems 
such as mammalian cells or yeast cells [10-13].  However, the question as to how these 
2 expression systems differ from each other is still uncertain; and even discrepant 
results have been obtained with these 2 experimental systems [14,15].  Thus, to 
conduct effective studies on the functional properties of CPT1, characterization of these 
2 expression systems is an utmost important issue to be clarified.   
   In the present study, we expressed rat CPT1b isozyme in COS7 cells and yeast cells, 
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and characterized the properties of the obtained mitochondrial fractions from these 
expression systems.  
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Materials and Methods 
 
Materials 
   COS7 cells were obtained from the Health Science Research Resources Bank 
(Osaka).  The haploid strain of Saccharomyces cerevisiae W303-1B (MATα ade2-1 
leu2-3, 112 his3-22, 15 trp1-1 ura3-1 can1-100) was used as yeast cells.  The Origami 
B(DE3)pLysS strain was purchased from Merck KGaA (Darmstadt, Germany).  The 
mammalian expression plasmid vector pCXN2 was a gift from Dr. Miyazaki [16].  
Dulbecco’s modified Eagle’s medium (DMEM) and fetal calf serum (FCS) were 
procured from Nissui (Tokyo) and Equitech-Bio (Kerrville, TX), respectively.  
Lipofectamine 2000 was purchased from Invitrogen Corp. (Carlsbad, CA); and 
L-[methyl-3H] carnitine hydrochloride (specific radioactivity: 3.11 TBq/mmol), from 
GE Healthcare UK, Ltd.  The BCA protein assay kit was purchased from TaKaRa Bio 
Inc. (Otsu Japan).   
 
Preparation of antiserum against rat CPT1b 
   Polyclonal antibody against rat CPT1b was raised in an adult New Zealand White 
rabbit as described in our previous report [17].  A peptide with the amino acid 
sequence of TGSHKKQDLQDLFRKASEC (amino acid 621–638, reported by 
Yamazaki et al. [18], plus one C-terminal Cys residue to confer reactivity with 
maleimide-activated keyhole limpet hemocyanin), was synthesized by means of a 
Shimadzu peptide synthesizer, model PSSM-8, and was used as the immunogen.   
 
cDNA encoding rat CPT1b 
   The DNA fragment corresponding to the open reading frame of the cDNA encoding 
CPT1b was prepared by PCR by using DS112-36 as a template [6].  Primers used for 
amplification of the cDNA were GE2321 
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(5’-ACTAAACCCCCATATGGCGGAAGCACAC) and GE2324 
(5’-TGTGGATCCTGGTCTCAGCTGTCAGTC). By using these 2 primers, restriction 
sites of NdeI and BamHI were created at the 5’ and 3’ end of the cDNA fragment, and 
these 2 restriction sites were used for preparation of the expression vectors.   
 
Bacterial expression of rat CPT1b 
   Bacterial expression of rat CPT1b was achieved in Origami B(DE3)pLysS strain, by 
using pColdIII/CPT1b as an expression vector.  Briefly, a culture of Origami strain 
harboring the pColdIII/CPT1b vector (250 ml) was incubated until its OD600 had 
reached 0.4.  Then, the protein expression inducer IPTG was added to a final 
concentration of 0.4 mM, and the cell suspension was further incubated at 15° C for 12 
hrs.  Cells were harvested by centrifugation, and re-suspended with 4 ml of TE.  The 
resulting cell suspension was subjected to 3 cycles of freeze/thaw/sonication, and the 
expressed CPT1b protein was recovered as the TE-insoluble precipitate, which was 
resuspended in 0.3 ml of TE and used as the standard protein of rat CPT1b.   
 
Expression of rat CPT1b in COS7 cells 
   Expression vector of rat CPT1b in mammalian cells was constructed by using 
pCXN2 [16].  For transient expression of rat CPT1b, expression vector pCXN2/CPT1b 
was introduced into COS7 cells by using Lipofectamine 2000, as described previously 
[18].   
 
Preparation of mitochondrial fraction from cultured COS7 cells 
   Two days after transfection, the cultured cells were harvested; and then they were 
suspended in ice-cold KCl medium (150 mM KCl and 5 mM Tris–Cl buffer, pH 7.2).  
Next, the cells were disrupted by homogenization with a Potter-type homogenizer.  
The obtained homogenate was centrifuged at 800×g, 4º C for 10 min, and unbroken 
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cells obtained as the pellet were subjected to further homogenization; and this procedure 
was repeated 3 times.  The cell lysates thus obtained were pooled and then centrifuged 
at 10,000×g, 4º C for 10 min.  The resulting pellet was resuspended in ice-cold KCl 
medium, and used as the mitochondrial fraction.   
 
Expression of rat CPT1b in yeast cells 
   The expression vector of rat CPT1b in yeast cells was constructed by using 
pYO326-YA2P [19].  For the expression of CPT1b, W303-1B cells were transformed 
with the expression vector pYO326-YA2P/CPT1b.   
 
Preparation of mitochondrial fraction from yeast cells 
   Preparation of the mitochondrial fraction from cultured yeast cells was performed 
essentially as described previously [20].  Briefly, yeast cells were twice washed with 
cold distilled water and then incubated in medium containing 10 mM dithiothreitol 
(DTT) and 0.1 M Tris–SO4, pH 8.0, at 30º C, after which they were centrifuged at 100 
rpm for 15 min.  The DTT-treated cells were resuspended in sorbitol medium (1.2 M 
sorbitol and 20 mM KPi, pH 7.4) and then incubated (30º C, 100 rpm, 15 min) with 
11.39 mg of zymolyase 20T in sorbitol medium per g of yeast cells to form spheroplasts.  
The spheroplasts were twice washed with sorbitol medium, and subsequently ground in 
mannitol medium (10 mM Tris–HCl, pH 7.4, containing 0.6 M mannitol, 0.1 mM 
EDTA, and 10 μM p-APMSF) at low speed in a chilled Potter–Elvehfem homogenizer.  
Next, the homogenate was centrifuged for 5 min at 800×g. The pellet was discarded, 
and the supernatant was centrifuged for 10 min at 6800×g. The resulting mitochondrial 
pellet was resuspended in mannitol medium.  
 
Measurements of protein concentration 
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   The protein concentration of mitochondrial fractions was measured by use of a BCA 
protein assay kit with bovine serum albumin as the standard.    
 
Measurements of CPT1 activity 
   Activity of CPT1b was measured according to the procedure described previously 
[18].  Briefly, the reaction was initiated by the addition of the mitochondrial fraction 
(50 μl containing about 30 μg mitochondrial protein) to a prewarmed reaction solution 
(450 μl) consisting of 150 mM KCl, 1 mM EDTA, 0.25 mM reduced glutathione, 1.3 
mg/ml fatty acid-free BSA, 0.5 mM L-carnitine, 50 μM palmitoyl-CoA, 2 mM KCN, 37 
kBq L-[methyl-3H] carnitine, and 50 mM Hepes buffer, pH 7.4.  After incubation at 30º 
C for 20 min, the reaction was terminated by the addition of 500 μl of 1.2 M HC1. The 
palmitoyl L-[methyl-3H]carnitine formed was extracted into 500 μl of n-butanol, and the 
butanol phase was back-extracted with 200 μl of water.  Then, 200 μl of the final 
organic phase was taken for liquid scintillation counting.  As described in our previous 
report, the formation of palmitoyl L-[methyl-3H] carnitine occurred in an incubation 
time-dependent manner at least up to 20 min.  Thus, the amount of palmitoyl 
L-[methyl-3H] carnitine formed by this time was used to calculate the activity of CPT1b.   
 
Western blotting  
   Expression levels of CPT1b in individual expression systems were evaluated by 
Western blotting according to the procedure described previously [14].  Specific 
antibody against CPT1b was prepared as stated above, and that against the β-subunit of 
F1-ATPase was prepared as described previously [14].   
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Results and discussion 
 
Comparison of yields of mitochondrial fractions and activities of expressed CPT1b 
between COS7 cells and yeast expression systems  
   As CPT1 is easily inactivated by solubilization with detergents, enzymatic activities 
of CPT1 are usually studied by using the mitochondrial fraction.  To discuss the 
usefulness of these 2 expression systems for studies on the properties of CPT1b, we 
considered it to be important to characterize these systems with respect to the following 
points: i) yield of mitochondrial fraction, ii) observable CPT1 activity of the 
mitochondrial fraction, and iii) properties of the expressed enzyme.  Thus, we first 
examined the yield of the mitochondrial fraction and observable CPT1 activity in it for 
the individual expression systems.   
   As starting materials, transfected cells in 2 culture dishes (100-mm diameter) and 
500 ml of YPgal culture having reached an OD600 of 0.8 – 1.2 were used for expression 
systems of COS7 cells and yeast cells, respectively.  We repeated preparation of the 
mitochondrial fraction from the individual expression systems more than 5 times, and 
the mean values ± SD (n = 3) of the yield of the mitochondrial fraction and observed 
CPT1 activity in it for each system are shown in Table I.   
   The amount of total protein in the cellular lysate obtained from yeast cells as a 
starting material was approximately 7-fold greater than that from the COS7 cells.  
Regardless of the use of relatively distinct amounts of total cellular proteins as starting 
materials, we recovered relatively similar amounts of proteins (i.e., 0.86 and 0.57 mg 
proteins) as mitochondrial fractions from these 2 expression systems.  Possibly these 
results indicate the higher purity of the mitochondrial fraction of yeast cells than that of 
COS7 cells.  It is quite reasonable that the use of larger numbers of cells as starting 
materials would be desirable for the preparation of mitochondrial fractions of higher 
purity.  We could easily increase the amount of total cellular proteins of COS7 cells by 
10 
 
using larger numbers of culture dishes; but in this case, the experimental cost would 
become significant.   
   We next assessed the CPT1b activity in the mitochondrial fraction from each 
cellular system.  As mentioned in our previous reports, the mitochondrial fraction 
prepared from COS7 cells transfected with a sham vector (specifying no cDNA of 
CPT1b) showed almost negligible catalytic activity, indicating the expression level of 
the endogenous CPT1 to have been very low.  Likewise, in the case of the yeast cells, 
there was almost negligible catalytic activity (data not shown).  On the contrary, when 
we assessed the enzymatic activity of CPT1b in the mitochondrial fractions prepared 
from COS7 cells and yeast cells, the values were similar, as shown in Table I.  In an 
exact sense, the activity observed for the mitochondrial fraction from the yeast cells was 
25% higher than that observed for the COS7 cells.  If we assume that the expression 
levels of CPT1b and specific activities of expressed CPT1b were identical between the 
2 mitochondrial fractions obtained from COS7 cells and yeast cells, the above results 
are quite reasonable.  This higher CPT1b activity observed for yeast mitochondria 
could be attributable to their higher purity than those of COS7 mitochondria.   
   We also examined the sensitivity of the expressed CPT1b from each expression 
system to its intrinsic metabolic inhibitor, malonyl-CoA.  As shown in Fig. 1, the 
enzyme from either system was inhibited more than 80% with 10 µM malonyl-CoA.  
However, at the lower concentration of 1 µM malonyl-CoA, the expressed CPT1b 
showed distinct sensitivities to the inhibitor; i.e., the activity of the enzyme from COS7 
cells was suppressed about 80%, whereas that from yeast cells was inhibited only 50%.  
The reason for this difference is uncertain.   
 
Preparation of standard CPT1b protein by bacterial expression system and its 
quantification by Coomassie staining 
   For further characterization of the mitochondrial fraction prepared from the 
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individual expression systems, evaluation of the amount of CPT1b in each seemed 
important.  To enable quantitative evaluation of the amounts of CPT1b in the 2 
mitochondrial preparations, we next prepared “standard” CPT1b by using a bacterial 
expression system.  We first tried to express CPT1b in E. coli strain BL21(DE3), but 
remarkable expression, i.e., that easily detectable by SDS-PAGE and subsequent 
Coomassie staining, was not achieved.  Thus, we further tested its expression in other 
strains, i.e., Rosetta 2(DE3)pLysS and Origami B(DE3)pLysS.  Although a satisfactory 
expression level of CPT1b was not obtained even by using these strains, CPT1b was 
slightly expressed in the Origami B(DE3)pLysS strain as inclusion bodies.  Thus, we 
collected the insoluble proteins from lysates of this bacterium.  When a sample of 
CPT1b protein thus prepared was subjected to SDS-PAGE and subsequent Coomassie 
staining, a protein band showing an estimated molecular size of CPT1b was observed as 
one of the major protein bands, as shown in Fig 2.  Ideally, a standard protein should 
have an amino acid sequence completely identical to that of the native protein, but the 
standard protein thus prepared had 6 additional amino acid residues 
(MetAsnHisLysValHis) encoded by the TEE (translation enhancing element) sequence 
in the pColdIII vector.  For this reason, in an exact sense, this standard protein (88.97 
kDa) would be expected to show a slightly slower migration than the native protein 
(88.22 kDa).  As this protein band was not observed with the bacterial lysate prepared 
from the E. coli strain in which the sham vector had been introduced, this protein band 
was suggested to be the expressed CPT1b.  The amount of CPT1b standard protein 
was quantified in terms of its staining intensity in polyacrylamide gel stained with 
Coomassie dye, with bovine serum albumin used as a standard.   
 
Use of specific antibody against CPT1b and standard CPT1b protein for quantification 
of CPT1b present in the mitochondrial fraction from each cellular system 
   We next assessed the amounts of CPT1b in the individual mitochondrial fractions 
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prepared from COS7 cells and yeast cells.  For this assessment, we first prepared a 
specific antibody against CPT1b by using a synthetic peptide as the immunogen.  
Specific reactivity of the raised antibody was confirmed by using bacterially expressed 
CPT1b as an authentic CPT1b (data not shown).  When the mitochondrial fraction 
prepared from either expression system was subjected to Western analysis using the 
specific antibody against CPT1b, a clear protein band was observed (Fig. 3).  As these 
protein bands were not observed with the mitochondrial fractions prepared from COS7 
cells and yeast cells in which sham expression vectors had been introduced, they were 
concluded to be the expressed CPT1b.  It should be emphasized that no 
immunostained band was observed with the mitochondrial fraction prepared from COS7 
cells transfected with the sham expression vector, thus indicating that the expression 
level of the endogenous CPT1b in this cell line was negligible.  As COS7 cells were 
derived from kidney tissue of an African green monkey, even if heart/muscle-type 
isozyme (CPT1b) was not detectable, the expression of the liver-type isozyme (CPT1a) 
could be considered.  However, even if liver-type isozyme (CPT1a) was expressed, its 
expression level would not have been high, because the mitochondrial fraction prepared 
from COS7 cells transfected with the sham vector showed almost negligible catalytic 
activity, as mentioned above.   
   Because we used a known amount (30 ng) of bacterially expressed CPT1b as a 
standard, we could determine the expression level of CPT1b in the individual 
mitochondrial fractions prepared from COS7 cells and yeast cells.  The amounts of 
CPT1b protein expressed in these fractions prepared from COS7 cells and yeast cells 
were determined to be 9.84 ± 0.94 ng/µg mitochondrial protein and 2.70 ± 0.66 ng/µg 
mitochondrial protein, respectively.  The CPT1b content in the mitochondrial fraction 
would be affected by various factors such as i) fraction purity, ii) promoter activity, or 
iii) stability of the CPT1b in the mitochondrial membrane.  The exact reason for the 
lower content of CPT1b in the mitochondrial fraction from the yeast cells is uncertain.  
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Of these factors, a difference in fraction purity between COS7 cells and yeast cells 
would be excluded as a probable answer, because the purity of the mitochondrial 
fraction from COS7 cells would be expected to be lower than that from yeast cells, as 
stated above.  The interpretation that mitochondria from yeast cells have a limited 
content of CPT1b would be reasonable, because a possible lower level of CPT1a in 
yeast mitochondria than in COS7 ones was also discussed by Swanson et al. [11], 
although they did not show detailed data on the quantification of its expression levels.   
   As we had determined the content of CPT1b in the mitochondrial fraction from each 
expression system, we could roughly estimate the specific activities of CPT1b protein 
obtained from the 2 systems.  The specific activities of CPT1b expressed in COS7 
cells and yeast cells under the present experimental conditions were determined to be 
0.62 and 3.00 µmol/mg protein/min, respectively.  We were surprised to find that 
CPT1b expressed by COS7 cells and yeast cells showed remarkably different specific 
activities: the enzyme expressed in yeast cells showed about 5 times higher specific 
activity than that expressed in COS7 cells.  The exact reason for this difference is 
uncertain, but we can suggest 2 probable answers.  First, in mammalian cells such as 
COS7 cells, the other members of the carnitine system, i.e., carnitine/acylcarnitine 
carrier and carnitine palmitorytransferase 2 (CPT2), are present in the mitochondrial 
membrane.  Although their expression levels seem not to be high, these members may 
have further processed the acylcarnitine formed by CPT1b.  However, these members 
are not present in the yeast mitochondrial membrane.  This difference may have caused 
the distinct specific activities of the expressed CPT1b.  A second possible answer is the 
difference in phospholipid content between mammalian and yeast mitochondria, which 
may have affected the activity of the membrane proteins.  To obtain an accurate 
explanation for the observed difference in the specific activity of the expressed CPT1b’s, 
further careful studies must be carried out.   
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Concluding remarks 
   For functional characterization of membrane proteins, expression systems using 
living cells are effective.  However, the answer to the question as to which one of the 
various expression systems using living cells is suitable for the target protein would be 
largely dependent upon the individual protein species.  In the present study, we 
characterized 2 cellular systems, one using COS7 cells and the other, yeast cells, for 
expression of CPT1b.  The yield of the mitochondrial fraction from yeast cells was 
higher than that from COS7 cells, but the expression level of CPT1b was higher in the 
mitochondrial fraction from COS7 cells than in that from yeast cells.  More 
importantly, the roughly estimated specific activity of CPT1b was higher for the yeast 
mitochondrial fraction than for the COS7 one.  Although the exact reason for the latter 
difference is still uncertain, the results obtained in this present study are important for 
further characterization of the CPT1 enzyme produced by different cellular expression 
systems.   
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Table I  Yield of mitochondrial fraction and observed CPT1 activity in it for each 
expression system 1) 
          expression system  
COS7 cells yeast cells 
obtained proteins 
(mg)  
in total cell lysate 3.40 ± 0.54 23.4 ± 4.7 
in mitochondrial 
fraction 
0.57 ± 0.02 0.86 ± 0.12 
CPT1 activity observed in the 
mitochondrial fraction  
(nmol/mg mitochondrial protein/min) 
6.92 ± 2.03 8.70 ± 0.80 
1) The cells in 2 culture dishes (100-mm diameter) and in 500 ml of YPgal culture 
reaching OD600 of 0.8 – 1.2 were used as starting materials for COS7 and yeast cell 
expression systems, respectively.  Mean values ± SD of independent runs are shown.  
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Legends for Figures 
 
Fig. 1.  Inhibition of CPT1b expressed in COS7 cells and yeast cells by malonyl-CoA 
   For examination of the sensitivities of CPT1b expressed in COS7 cells and yeast 
cells toward malonyl-CoA, activities of CPT1b in these preparations were measured in 
the presence of various concentrations of malonyl-CoA, and their values relative to 
those observed in the absence of malonyl-CoA were plotted as a function of the 
malonyl-CoA concentration.  Open circles and closed circles represent the data 
obtained with mitochondrial fractions from COS7 cells and yeast cells, respectively; 
and the perpendicular lines attached to the individual circles indicate standard 
deviations.  Activities of CPT1b expressed in COS7 cells and yeast cells in the absence 
of malonyl-CoA were 6.92 and 8.70 nmol/mg mitochondrial protein/min, respectively, 
as shown in Table I.   
 
Fig. 2.  Preparation of standard CPT1b protein by a bacterial expression system  
   CPT1b protein slightly expressed as inclusion bodies in Origami B(DE3)pLysS 
bacteria was collected by centrifugation.  It was then resuspended in 0.3 ml of TE and 
partially purified by repeated centrifugation.  A 10-µl aliquot of the obtained 
suspension was subjected to SDS-PAGE using 7.5%T acrylamide gel.  The major 
protein band highlighted with an asterisk is the expressed CPT1b.   
 
Fig. 3.  Expression-level analysis of CPT1b in the mitochondrial fractions prepared 
from COS7 cells and yeast cells by use of Western blotting with antibody specific for 
CPT1b 
   For evaluation of CPT1b expression levels, aliquots (5 µg protein) of the 
mitochondrial fraction prepared from COS7 cells or yeast cells transfected with 
individual expression vectors of CPT1b (designated as “cDNA +”) were subjected to  
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Western blotting.  Mitochondrial fractions from cells transfected with sham expression 
vectors (designated as “cDNA –“) were used as negative controls.  For quantification 
of the expressed CPT1b, a known amount (30 ng) of bacterially expressed CPT1b was 
immunoblotted as a standard (designated as “STD”).  CPT1b proteins in the individual 
samples were detected with the specific antibody and visualized by use of an ECL kit.  
Expression levels of CPT1b were determined from the signal intensities of the 
fluorograms (upper photograph).  The β-subunit of F1-ATPase (designated as “F1β”) 
present in individual protein samples was also detected as a control.  To ascertain that 
equal amounts of proteins had been loaded onto the gel, aliquots of each mitochondrial 
fraction (10 µg protein) were subjected to SDS-PAGE and stained with CBB (lower 
photograph).  
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